Latest Update On COVID 19 Vaccine Development

Vaccine candidate(developer/sponsor) Technology Phase of trial(participants) Adverse effects Immune response Location Duration AZD1222(University of Oxford, AstraZeneca) adenovirus vector Phase II–III randomized, interventional (10,260) pending Phase I report pending Phase I report United Kingdom May 2020…Continue Reading →